Alcinous to use $50K Innovation Voucher to create new PARP inhibitor

Emily Gowdey-Backus

12/08/2017

TEAM MEETING: From left, Brenton DeBoef, professor of chemistry at the University of Rhode Island, and Alcinous Pharmaceutical team members Nicholas DaSilva, CEO and Ph.D. student in the URI College of Pharmacy; Benjamin Barlock, chief technology officer and Ph.D. student in the URI College of Pharmacy; David Worthen, chief operations officer and URI assistant professor in the Department of Biomedical and Pharmaceutical Sciences and the Department of Chemical Engineering; and Ken Rose, chief scientific officer and Ph.D. student in the URI College of Pharmacy, discuss Alcinous’ latest research project. / PBN PHOTO/RUPERT WHITELEY

Five weeks prior to celebrating its first year in business, Alcinous Pharmaceuticals received a $50,000 Innovation Voucher from R.I. Commerce Corp. The microcompany had been pursuing the state funding for quite a while, said Ken Rose, chief scientific officer, adding the announcement was a “relief.” One of three companies approved to receive voucher funding in

Already a Subscriber? Log in

To Continue Reading This Article

Become a Providence Business News subscriber and get immediate access to all of our premier content and much more.

Learn More and Become a Subscriber